Ocuphire's Phase 3 VEGA-3 presbyopia trial posts results on ClinicalTrials.gov

Ocuphire Pharma had one update this week, with results posted for its completed Phase 3 presbyopia study.

• Ocuphire Pharma's Phase 3 study of phentolamine ophthalmic solution (POS) 0.75%, called VEGA-3, is a randomized, double-masked, placebo-controlled trial in participants with presbyopia that completed on 2026-01-22 with results posted 2026-08-17.¹ The study enrolled 569 participants.¹ Its primary endpoint measured the percentage of subjects with at least 15 letters of improvement in binocular distance-corrected near visual acuity and less than 5 letters of loss in binocular best-corrected distance visual acuity, comparing POS to placebo at 12 hours post-dose on Day 8.¹